Increased NF-L levels in the TDP-43<sup>G298S</sup> ALS mouse model resemble NF-L levels in ALS patients

Eva Buck<sup>1</sup> · Patrick Oeckl<sup>1,2</sup> · Veselin Grozdanov<sup>2</sup> · Verena Bopp<sup>2</sup> · Julia K. Kühlwein<sup>2</sup> · Wolfgang P. Ruf<sup>2</sup> · Diana Wiesner<sup>1</sup> · Francesco Roselli<sup>1,2</sup> · Jochen H. Weishaupt<sup>2,3</sup> · Albert C. Ludolph<sup>1,2</sup> · Markus Otto<sup>2,4</sup> · Karin M. Danzer<sup>1,2</sup>

Received: 14 December 2021 / Revised: 11 May 2022 / Accepted: 11 May 2022 / Published online: 18 May 2022
© The Author(s) 2022

Elevated levels of neurofilament light chain (NF-L) in CSF and blood are linked to the presymptomatic and symptomatic phase of patients suffering from amyotrophic lateral sclerosis (ALS). However, whether the NF-L level in extracellular liquids like serum or CSF is a marker of destruction or NF-L is secreted actively outside the cell is not known so far. NF-L levels in CSF and blood clearly separate ALS patients and controls [9], serving as a prognostic biomarker for ALS [4]. Also in pre-symptomatic ALS gene mutation carriers NF-L levels are elevated thus allowing prediction for clinical phenocconversion [3, 4]. The picture of NF-L levels in ALS mouse models is less clear. Previous studies report on elevated NF-L plasma levels in SOD<sup>1G93A</sup> and TDP-43 (TAR6/6) mice [6], but the correlation to motor neuron (MN) loss has not been determined. We therefore employed a transgenic TDP-43<sup>G298S</sup> mouse model to study the interaction of motor neuron pathophysiology, muscle denervation and NF-L levels. TDP-43<sup>G298S</sup> mutant mice show decreased performance in grip strength and motor activity compared to controls [10].

Serum NF-L level measurements were carried out with the ultrasensitive single molecule array (Simoa) technique and showed a significant age- and genotype-dependent increase of NF-L in both WT and TDP-43<sup>G298S</sup> mice (****p < 0.0001 for age, **p < 0.01 for genotype, Two-Way ANOVA with Tukey’s multiple comparison test) (Fig. 1a). In contrast to WT mice TDP-43<sup>G298S</sup> mice had increased NF-L levels already at 2–3 months of age that continuously raised until reaching a plateau at 8 months (****p < 0.001 for 2 months, *p < 0.05 for 8 months, *p < 0.05 for 18 months; Mann–Whitney test comparison WT vs TDP-43<sup>G298S</sup>). WT mice needed 12 months longer to reach the same plateau as TDP-43<sup>G298S</sup> mice, thus potentially pointing to a premature aging phenotype or to early MN degeneration in TDP-43<sup>G298S</sup> mice. These findings are in line with previous studies demonstrating increased NF-L levels at 9 and 27 weeks of age in transgenic TDP-43 (TAR6/6) and SOD<sup>1G93A</sup> mice, respectively [6]. From 10 months onward, NF-L levels are constantly high in our TDP-43<sup>G298S</sup> mouse model compared to controls and are in line with clinical data from ALS patients [3, 4, 8].

To study whether destructive processes in MN pathophysiology might be the underlying cause of NF-L level increase, the number and area of MNS in the ventral horn of the lumbar spinal cord were determined. Again, as also seen for NF-L levels, already at the age of 2 months TDP-43<sup>G298S</sup> mice differed significantly from WT mice showing reduced MN counts comparable to the MN count of WT mice at older ages like 10 or 18–20 months (*p < 0.05, Mann–Whitney test and **p < 0.01 for age Two-Way ANOVA with Tukey’s multiple comparison test) (Fig. 1b, c). This MN loss in WT mice with age has been shown before [7]. These results support the idea that NF-L levels correlate with degenerating or damaged MNS. Since it is known that larger MNS are more affected in ALS [5], we measured the area of all counted MNS and found a significant decrease in MN cell body area in TDP-43<sup>G298S</sup> mice with age compared to controls (Two-Way ANOVA for statistical analysis age (****p < 0.001), genotype (*p < 0.05)
and interaction of both (***p < 0.001)) (Fig. 1d). Cell body swelling of MN in 27 months old mice compared to 3–6 months old ones has been reported previously [7]. In contrast to this, we did not observe increased MN area in old mice (max. 20 months old). Since we saw larger neurons in TDP-43^G289S^ mice already at 2 months of age we speculate that this type of MNs is highly vulnerable in ALS building the basis for MN degeneration already
Fig. 1 Age and disease dependent changes in TDP-43ΔG298S mice according to serum NF-L levels, NMI integrity, MN count and area. a Serum NF-L levels were determined in WT and TDP-43ΔG298S transgenic mice at 2–3 months, 8 months, 10 months, 18 months and 20 months of age by single molecule array (Simoa) technology. Data distribution is shown as box plots (box showing the 25% and 75% percentile, with the line as median and the + indicating the mean, which is connected by lines, whiskers show min and max) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Two-Way ANOVA with Tukey’s multiple comparison test. Significant differences between genotypes of one age group were determined by Mann–Whitney test (green) *p < 0.05, ***p < 0.001, n = 7–14, every time point reflects an end point measurement. b The number of motor neurons (MN) was determined in WT and TDP-43ΔG298S mice in the ventral horn of the lumbar spinal cord (LSC). Representative pictures of the counted areas of the ventral horn are shown. Neurotrace (NT, red) and choline acetyltransferase (Chat, green) positive cells were counted in 4–10 sections per animal (WT/TDP-43ΔG298S: (2mo) n = 9/9; (10mo) n = 4/4; (18–20mo) n = 5/9). Scale bar represents 50 µm. c Statistical analysis of MN counts was performed by Two-Way ANOVA with Tukey’s multiple comparison test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Significant differences between genotypes of one age group were determined by Mann–Whitney test (green) (p < 0.05). Data are shown as box plots n = 4–9. d MN area was marked and measured in LSC sections of the mice using image J software. Using Two-Way ANOVA for statistical analysis (green) *p < 0.01, **p < 0.001, ****p < 0.0001) and should be investigated in further studies. In addition the sequencing data revealed that TDP-43ΔG298S expression in our mouse model does not alter mRNA expression levels of Nfli although it is known that these are binding partners (supplemental Fig. 2a). The amount of denervated (partly or complete) NMJs was determined according to the overlap of the presynaptic synapsin (red) and α-bungarotoxin immuno- fluorescence signal (Fig. 1e, f). The images in Fig. 1e are representative images but the quantification in Fig. 1f illustrates the pooled data from denervated and partly denervated NMJs. TDP-43ΔG298S mice at 2 months as well as 10 months showed increased denervation compared to WT mice (p < 0.05 Mann–Whitney test, **p < 0.01 Two-Way ANOVA with Tukey’s multiple comparison test and p < 0.05 Mann–Whitney test comparison of only two defined groups).

To further characterize ALS related alterations in TDP-43ΔG298S mice, we performed immunohistochemistry and observed that the overlap between TDP-43 and nuclear staining is less pronounced in TDP-43ΔG298S g animals than in WT mice (Two-Way ANOVA for statistical analysis showed significant changes for the genotype with p < 0.05) (supplemental Fig. 1a, b). In addition, we conducted RNA sequencing of the cortex of these mice for all age groups and identified genes that were significantly altered in each respective group, even at the early age of 2 months (Fig. 1g). Further analysis of the RNA sequencing data showed six genes, which show clearly a genotype specific regulation (supplemental Fig. 2a). The Venn diagram of the most significant hits again illustrates the separation of the groups by age and highlights one very significant candidate in common, namely the mitochondrial protein Glycerol-3-phosphate dehydrogenase (Gpd2) (Fig. 1h), which is also dysregulated in the ALS SOD1 mouse model [1] as well as the wobbler mouse [2], a model of motor neuron degeneration. Gpd2 reliably differentiates between WT and TDP-43ΔG298S animals throughout all groups of age (Fig. 1i) and should be investigated in further studies. In addition the sequencing data revealed that TDP-43ΔG298S expression in our mouse model does not alter mRNA expression levels of Nfli although it is known that these are binding partners (supplemental Fig. 2b).

Together, the present study demonstrates that ALS TDP-43ΔG298S mice recapitulate elevated serum NF-L levels as seen in ALS patients. Simultaneously to NF-L elevation MN loss and muscle denervation were detected suggesting that NF-L elevation might be due to MN degeneration. We conclude that this mouse model is suitable for biomarker research in ALS with regard to the specific mechanisms involved in the disease associated release of NF-L.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00401-022-02436-1.

Acknowledgements We are thankful for the TDP-43ΔG298S mouse model, which was a gift of Prof. Philip Wong. We thank Ramona Bück, Alina Erk and Tanja Christ for their excellent technical assistance. This work was supported by the Baustein program of Ulm University and the Deutsche Forschungsgemeinschaft (DFG) Emmy Noether Research Group DA 1657/2-1 (EB and KMD).

Funding Open Access funding enabled and organized by Projekt DEAL. Emmy Noether Research Group DA 1657/2-1 (KMD). Karin M Danzer, Universität Ulm, LSBN0.167, Eva Buck.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Basso M, Samengo G, Nardo G, Massignan T, D’Alessandro G, Tartari S et al (2009) Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS ONE 4:e8130. https://doi.org/10.1371/journal.pone.0008130
2. Bastone A, Fumagalli E, Bigini P, Perini P, Bernardinello D, Cagnotto A et al (2009) Proteomic profiling of cervical and lumbar spinal cord reveals potential protective mechanisms in the wobbler mouse, a model of motor neuron degeneration. J Proteome Res 8:5229–5240. https://doi.org/10.1021/pr900569d
3. Benatar M, Wu J, Andersen PM, Lombardi V, Malaspina A (2018) Neurofilament light: a candidate marker of presymptomatic amyotrophic lateral sclerosis and phenocconversion. Ann Neurol 84:130–139. https://doi.org/10.1002/ana.25276
4. Benatar M, Zhang L, Wang L, Granit V, Statland J, Barohn R et al (2020) Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95:e59–e69. https://doi.org/10.1212/WNL.0000000000009559
5. Conradi S, Ronnevi LO (1993) Selective vulnerability of alpha motor neurons in ALS: relation to autoantibodies toward acetylcholinesterase (AChE) in ALS patients. Brain Res Bull 30:369–371. https://doi.org/10.1016/0361-9230(93)90267-f
6. Loeffler T, Schilcher I, Flunkert S, Hutter-Paier B (2020) Neurofilament-light chain as biomarker of neurodegenerative and rare diseases with high translational value. Front Neurosci 14:579. https://doi.org/10.3389/fnins.2020.00579
7. Piekarz KM, Bhaskaran S, Saratatarajan K, Street K, Premkumar P, Saunders D et al (2020) Molecular changes associated with spinal cord aging. GeroScience 42:765–784. https://doi.org/10.1007/s11357-020-00172-6
8. Steinacker P, Huss A, Mayer B, Grehl T, Grosskreutz J, Borck G et al (2017) Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener 18:112–119. https://doi.org/10.1080/21678421.2016.1241279
9. Weydt P, Oeckl P, Huss A, Muller K, Volk AE, Kuhle J et al (2016) Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 79:152–158. https://doi.org/10.1002/ana.24552
10. Wiesner D, Tar L, Linkus B, Chandrasekar A, Olde Heuvel F, Dupuis L et al (2018) Reversible induction of TDP-43 granules in cortical neurons after traumatic injury. Exp Neurol 299:15–25. https://doi.org/10.1016/j.expneurol.2017.09.011

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.